Camizestrant · Etcamah
Small molecule
Evidence outlook
Accelerated approval: HR+/HER2- Metastatic Breast Cancer, Breast Cancer
Accelerated approval is granted on surrogate endpoints; confirmatory clinical benefit is being verified in ongoing trials. Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
track record: Reliable signal
Also approved (1)
- Etcamah in combination with a CDK4/6 inhibitor (palbociclib, ribociclib, or abemaciclib) is indicated for the treatment of adult patients with ER-positive, HER2-negative, locally advanced or metastatic breast cancer upon detection of ESR1‑mutation and without disease progression during first-line endocrine therapy in combination with a CDK4/6 inhibitor (for biomarker based patient-selection, see section 4.2 and 5.1).
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
SERENA-4 NCT04711252 · ER-Positive HER2-Negative Breast Cancer Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence. Registry: NCT04711252 | 3 | Progression-free survival (PFS) assessed by the Investigator as defined by response evaluation criteria in solid tumors (RECIST) version 1.1 (From randomization until progression per RECIST 1.1 as assessed by the investigator at local site or death due to any cause (up to 5 years)) 2026-06-26 | SERENA-4 (NCT04711252): camizestrant plus palbociclib did not meet the primary endpoint of statistically significant PFS improvement vs anastrozole plus palbociclib, though a numerical improvement favoring camizestrant was observed. | not yet graded | link ↗ |
View 2 more trials
SERENA-6 NCT04964934 · ER-Positive HER2-Negative Breast Cancer This was a randomized, triple-blinded, placebo-controlled Phase III trial with an active comparator (continued aromatase inhibitor) in 315 patients, using progression-free survival (a hard clinical endpoint) as the primary measure. The result, reported via an external source since CT.gov has not yet posted results, showed a clear and highly statistically significant benefit for camizestrant (median PFS 16.0 vs 9.2 months, HR 0.44, p<0.00001), meeting the primary endpoint in the favorable direction. Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence. Registry: NCT04964934 | 3 | Progression-free survival (PFS) assessed by the Investigator as defined by response evaluation criteria in solid tumors (RECIST version 1.1) (From randomization until the earlier of the progression event or death (approximately 2 years)) 2025-06-30 | SERENA-6 (NCT04964934), primary endpoint PFS: median PFS 16.0 months (camizestrant + CDK4/6i) vs 9.2 months (aromatase inhibitor + CDK4/6i); HR 0.44 (95% CI 0.31-0.60); p<0.00001 | Reliable signal | link ↗ |
SERENA-3 NCT04588298 · HR+/HER2- Metastatic Breast Cancer Although participants were randomized among camizestrant dose groups, the study was open-label and had no placebo or active comparator; the primary endpoint was a surrogate biomarker, change in tumor ER expression, rather than a clinical outcome. Reported ER expression decreased across groups, but there was no controlled primary endpoint comparison to establish treatment benefit. Registry: NCT04588298 | 2 | Percentage Change From Baseline in Estrogen Receptor (ER) Expression Between Pre- and On-treatment Tumour Samples (Primary Analysis) (Baseline (Screening Day -21 to 1) to Biopsy day (Days 5-7 [Stage 1 and 2] or Days 12-15 [Stage 3])); Percentage Change From Baseline in ER Expression Between Pre- and On-treatment Tumour Samples (Sensitivity Analysis) (Baseline (Screening Day -21 to 1) to Biopsy Day (Days 5-7 [Stage 1 and 2] or Days 12-15 [Stage 3])) 2023-06-19 | Percentage Change From Baseline in Estrogen Receptor (ER) Expression Between Pre- and On-treatment Tumour Samples (Primary Analysis) (Baseline (Screening Day -21 to 1) to Biopsy day (Days 5-7 [Stage 1 and 2] or Days 12-15 [Stage 3])): AZD9833 75 mg (Stage 1 + 2) -62.7% (95% CI -67.46--57.93) vs AZD9833 150 mg (Stage 1 + 2) -62.8% (95% CI -67.13--58.43) vs AZD9833 300 mg (Stage 2) -67.1% (95% CI -74.49--59.74) vs AZD9833 75 mg (Stage 3) -66.9% (95% CI -72.34--61.46) vs AZD9833 150 mg (Stage 3) -65.0% (95% CI -70.27--59.81) | Weak signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (6)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (2)
What this study did
What this study did
Phase 1 (9)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Competitive landscape
Other Estrogen receptor drugs
Elacestrant, Fulvestrant, Imlunestrant, Tamoxifen (Soltamox), Vepdegestrant and 3 more. Compare all 9 Estrogen receptor drugs
This mechanism is crowded: 8 other tracked programmes target it, none of them ahead of this one.
This drug's own stage for HR+/HER2- Metastatic Breast Cancer: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Camizestrant (Etcamah): this drug | Approved | Small molecule | Estrogen receptor | Reliable signal | NCT04964934: SERENA-6 (NCT04964934), primary endpoint PFS: median PFS 16.0 months (camizestrant + CDK4/6i) vs 9.2 months (aromatase inhibitor + CDK4/6i); HR 0.44 (95% CI 0.31-0.60); p<0.00001 NCT04588298: Percentage Change From Baseline in Estrogen Receptor (ER) Expression Between Pre- and On-treatment Tumour Samples (Primary Analysis) (Baseline (Screening Day -21 to 1) to Biopsy day (Days 5-7 [Stage 1 and 2] or Days 12-15 [Stage 3])): AZD9833 75 mg (Stage 1 + 2) -62.7% (95% CI -67.46--57.93) vs AZD9833 150 mg (Stage 1 + 2) -62.8% (95% CI -67.13--58.43) vs AZD9833 300 mg (Stage 2) -67.1% (95% CI -74.49--59.74) vs AZD9833 75 mg (Stage 3) -66.9% (95% CI -72.34--61.46) vs AZD9833 150 mg (Stage 3) -65.0% (95% CI -70.27--59.81) | |
| Abemaciclib (Verzenio) | Approved | Small molecule | CDK4 and CDK6 | Reliable signal | NCT02107703: Progression-Free Survival (PFS) (From Date of Randomization until Disease Progression or Death Due to Any Cause (Up To 31 Months)): Abemaciclib + Fulvestrant 16.4 Months (95% CI 14.4 to 19.3) vs Placebo + Fulvestrant 9.3 Months (95% CI 7.4 to 11.4) NCT02102490: Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR]) (From Date of First Dose until Disease Progression or Death Due to Any Cause (Up To 14 Months)): Abemaciclib 19.7% (95% CI 13.3 to 27.5) | |
| Alpelisib (BYL719) | Approved | Small molecule | PI3K-alpha | Reliable signal | NCT02437318: Progression-free Survival (PFS) Per Investigator Assessment in the PIK3CA Mutant Cohort (Once approximately 243 PFS events in the PIK3CA mutant cohort had been observed, up to 33.3 months): PIK3CA Mutant Cohort by Tumor Tissue: Alpelisib + Fulvestrant 11 Months (95% CI 7.49 to 14.52) vs PIK3CA Mutant Cohort by Tumor Tissue: Placebo + Fulvestrant 5.7 Months (95% CI 3.65 to 7.36) | |
| Anastrozole | Approved | Small molecule | Aromatase | not yet graded | NCT00291759: Recurrence-free survival, 2yr tamoxifen then 3yr anastrozole vs 5yr tamoxifen: HR 0.80 (95% CI 0.63-1.01), P=.06 (not statistically significant) missed phase 3 result · pivotal pending NCT00300508: At a median follow-up of 62.3 months, women who received anastrozole (n=387) had a statistically significantly reduced risk of recurrence (locoregional recurrence, contralateral breast cancer or distant metastasis) versus women who received no further treatment (n=469): hazard ratio 0.62 (95% CI 0.40-0.96), P=.031. phase 3 result · pivotal pending | |
| Capecitabine | ApprovedUS marketing discontinued | Small molecule | Fluoropyrimidine (antimetabolite) | not yet graded | No reviewed efficacy summary in this indication | |
| Capivasertib | Approved | Small molecule | AKT (inhibitor) | Reliable signal | NCT04305496: Progression Free Survival: Overall Population (Months) in the Global Cohort (Assessed every 8 weeks for the first 18 months and every 12 weeks thereafter, from randomization to radiological progression.): Capivasertib + Fulvestrant (Global + China Cohort) 7.2 Months (95% CI 5.5 to 7.4) vs Placebo + Fulvestrant (Global + China Cohort) 3.6 Months (95% CI 2.8 to 3.7) NCT01625286: Progression-free survival, Part B (randomized vs placebo + paclitaxel): median 10.9 months (95% CI 8.3 to 12.4) with capivasertib vs 8.4 months (95% CI 8.2 to 10.8) with placebo; HR 0.80 (95% CI 0.60 to 1.06), p=0.308 (CT.gov posted results). missed | |
| Datopotamab Deruxtecan | Approved | Antibody–drug conjugate | TROP2 | Partial signal | NCT05104866: Progression-Free Survival (On-study tumor assessments occur every 6 weeks then every 9 weeks until disease progression, death or withdrawal of consent assessed up to data cut-off (17Jul2023) to a maximum of approximately 21 months): Dato-DXd 6.9 Months (95% CI 5.7 to 7.4) vs Investigator's Choice of Chemotherapy (ICC) 4.9 Months (95% CI 4.2 to 5.5) | |
| Docetaxel (Taxotere) | Approved | Small molecule | Microtubules (tubulin) | Partial signal | NCT00002662: ORR (the registered first objective) 32% vs 25% (P=.10); OS 15.4 vs 12.7 months (P=.03) and TTP 5.7 vs 3.6 months (P<.0001) favored docetaxel. missed | |
| Elacestrant | Approved | Small molecule | Estrogen receptor | Partial signal | NCT03778931: Progression-free Survival in ESR1-mut Participants (From Date of Randomization until Disease Progression or Death Due to Any Cause (up to 12 Months)): Elacestrant 3.78 months (95% CI 2.17 to 7.26) vs Standard of Care (SoC) 1.87 months (95% CI 1.87 to 2.14) | |
| Eribulin Mesylate | Approved | Small molecule | Tubulin / microtubules | Partial signal | NCT02225470: Progression-Free Survival, eribulin vs vinorelbine (independent tumor assessment): HR 0.80 (95% CI 0.65-0.98, P=0.036) in favor of eribulin; median PFS 2.8 months in both arms NCT00337103: Co-primary endpoints, eribulin (n=554) vs capecitabine (n=548): overall survival median 15.9 vs 14.5 months, HR 0.88 (95% CI 0.77 to 1.00), P = .056; progression-free survival median 4.1 vs 4.2 months, HR 1.08 (95% CI 0.93 to 1.25), P = .30 (Kaufman et al., J Clin Oncol 2015). missed | |
| Everolimus | Approved | Small molecule | mTOR kinase, mTOR (mTORC1) (inhibitor) | Weak signal | NCT02511639: Median progression-free survival: 9.9 months (everolimus + aromatase inhibitor) vs 7.2 months (aromatase inhibitor alone); HR 0.764 (95% CI 0.501-1.164) NCT00863655: Progression-free Survival (PFS) Based on Local Radiology Review of Tumor Assessments. (date of randomization to the date of first documented tumor progression or death from any cause, whichever occurs first, reported between day of first patient randomized up to about 19 months): Everolimus + Exemestane 6.93 months (95% CI 6.44 to 8.05) vs Placebo + Exemestane 2.83 months (95% CI 2.76 to 4.14) | |
| Exemestane | Approved | Small molecule | Aromatase | Partial signal | NCT00002777: Objective response rate: 46% exemestane vs 31% tamoxifen (odds ratio 1.85, 95% CI 1.21-2.82, P=.005). Median progression-free survival (the trial's primary endpoint): 9.9 months exemestane vs 5.8 months tamoxifen; long-term log-rank P=.121 (not statistically significant). missed | |
| Fulvestrant (Faslodex) | Approved | Small molecule | Estrogen receptor | Partial signal | NCT01602380: Comparison of Progression-Free Survival (PFS) in Patients Treated With Fulvestrant With Those Treated With Anastrozole (Baseline RECIST 1.1 assessments (Day 0) and then every 12 weeks until the earliest of disease progression evident, patient dies or has surgery/radiotherapy for their disease (up to approximately 38 months)): Fulvestrant 500 mg 16.6 Months (95% CI 13.83 to 20.99) vs Anastrozole 1 mg 13.8 Months (95% CI 11.99 to 16.59) NCT00099437: Progression-free survival: fulvestrant 500 mg (n=362) vs 250 mg (n=374), HR 0.80 (95% CI 0.68 to 0.94), P = .006; CT.gov median time to progression 6.5 vs 5.5 months (Di Leo et al., J Clin Oncol 2010). | |
| Gedatolisib (Revtorpyk) | Approved | Small molecule | PI3K (class I isoforms) and mTORC1/mTORC2 | Partial signal | NCT05501886: VIKTORIA-1 (NCT05501886), PIK3CA wild-type cohort, primary endpoint PFS: gedatolisib+fulvestrant+palbociclib (triplet) median PFS 9.3 months vs fulvestrant alone 2.0 months, HR 0.24 (95% CI 0.17-0.35), p<0.0001; gedatolisib+fulvestrant (doublet) median PFS 7.4 months, HR 0.33 (95% CI 0.24-0.48), p<0.0001. | |
| Gemcitabine | ApprovedUS marketing discontinued | Small molecule | ribonucleotide reductase / DNA polymerase (dCTP competition) | Weak signal | NCT00128310: Median progression-free survival: 6.0 months (gemcitabine + vinorelbine) vs 4.0 months (vinorelbine alone); hazard ratio 0.66 (p=0.0028). Overall survival not significantly different (15.9 vs 16.4 months, p=0.8046) NCT00006459: Eli Lilly's pivotal phase III global registration trial of gemcitabine + paclitaxel vs paclitaxel alone in anthracycline-pretreated advanced breast cancer, matching this listing's title/sponsor. Primary endpoint (overall survival): 18.6 vs 15.8 months, HR 0.78 (95% CI 0.64-0.96), p=0.0187, favoring the gemcitabine combination. | |
| Goserelin | Approved | Peptide | GnRH receptor (agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Imlunestrant (Inluriyo) | Approved | Small molecule | Estrogen receptor | Partial signal | NCT04975308: Investigator-assessed PFS. ESR1-mutated population: imlunestrant 5.49 vs 3.84 months with standard endocrine therapy, HR 0.617 (95% CI 0.464 to 0.821), p=0.0008. All patients: 5.55 vs 5.52 months, HR 0.867 (95% CI 0.724 to 1.039), p=0.1158 (not significant). Imlunestrant plus abemaciclib vs imlunestrant: 9.36 vs 5.49 months, HR 0.569 (95% CI 0.441 to 0.733), p<0.0001 | |
| Inavolisib (Itovebi) | Approved | Small molecule | PI3K-alpha | Reliable signal | NCT04191499: Progression-Free Survival (PFS) (Up to 3.7 years): Inavo+Palbo+Fulv 15 months (95% CI 11.3 to 20.5) vs Pbo+Palbo+Fulv 7.3 months (95% CI 5.6 to 9.3) | |
| Ixabepilone | Approved | Small molecule | Microtubules (tubulin) | Partial signal | Featured results are non-efficacy only in this race | |
| Letrozole | Approved | Small molecule | Aromatase | not yet graded | NCT00003140: Estimated 4-year disease-free survival: letrozole 93% vs placebo 87% (75 vs 132 recurrences/new cancers out of 5187 enrolled); P<=0.001 phase 3 result · pivotal pending NCT00004205: Disease-free survival (primary endpoint), letrozole vs tamoxifen: 5-year DFS 84.0% vs 81.4%; HR 0.81 (95% CI 0.70-0.93), P=0.003, at median follow-up 25.8 months (351 vs 428 events; N=8010). phase 3 result · pivotal pending | |
| Nab-Paclitaxel | Approved | Small molecule | Microtubules | Partial signal | NCT00785291: Progression Free Survival (Time from randomization to progression or death due to any cause, whichever occurs first (up to 5 years)): Arm B (Nab-paclitaxel) 9.3 months (95% CI 8.15 to 10.45) vs Arm A (Paclitaxel) 10.97 months (95% CI 9.79 to 12.42) vs Arm C (Ixabepilone) 7.36 months (95% CI 6.21 to 8.18) missed | |
| Olaparib | Approved | Small molecule | PARP | Partial signal | NCT02000622: Progression-free Survival (PFS) Using Blinded Independent Central Review (BICR) According to Modified Response Evaluation Criteria In Solid Tumours (RECIST v1.1) (Radiological scans performed at baseline then every ~6 weeks up to 24 weeks, then every ~ 12 weeks thereafter until objective radiological disease progression. Assessed up to a maximum of 30 months.): Olaparib 300 mg bd 7 Months (95% CI 5.7 to 8.3) vs Chemotherapy 4.2 Months (95% CI 2.8 to 4.3) NCT03286842: Progression-free Survival (PFS) in Real-world Setting in Germline BRCA Mutated Participants (At every visit until the earliest of disease progression, death or end of study (up to 3 years)): Olaparib gBRCAm Cohort 8.18 months (95% CI 6.97 to 9.17) | |
| Palbociclib (Ibrance) | Approved | Small molecule | CDK4 and CDK6 | Reliable signal | NCT02297438: Progression-Free Survival (PFS) Based on Investigator's Assessment: Up to Primary Completion Date (Randomization up to 65 months): Palbociclib + Letrozole 21.5 Months (95% CI 16.6 to 24.9) vs Placebo + Letrozole 13.9 Months (95% CI 13.7 to 16.6) NCT01740427: Progression-Free Survival (PFS) as Assessed by the Investigator (From randomization date to date of first documentation of progression or death (up to approximately 2.5 years)): Palbociclib Plus Letrozole 24.8 Months vs Placebo Plus Letrozole 14.5 Months (95% CI 12.9 to 17.1) | |
| Ribociclib | Approved | Small molecule | CDK4 and CDK6 | Reliable signal | NCT02422615: Progression Free Survival (PFS) Per Investigator Assessment (From randomization to first documented progression or death, assessed up to approximately 26 months): Ribociclib + Fulvestrant 20.5 Months (95% CI 18.5 to 23.5) vs Placebo + Fulvestrant 12.8 Months (95% CI 10.9 to 16.3) NCT02278120: Progression Free Survival (PFS) by Investigator Assessment (From randomization to first documented progression or death, assessed up to approximately 29 months): Ribociclib + NSAI/Tamoxifen + Goserelin 23.8 Months vs Placebo + NSAI/Tamoxifen+ Goserelin 13 Months (95% CI 11 to 16.4) | |
| Sacituzumab Govitecan | Approved | Antibody–drug conjugate | TROP2 | Partial signal | NCT03901339: Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) Assessment (Up to 42.8 months): Sacituzumab Govitecan 5.5 months (95% CI 4.2 to 6.9) vs Treatment of Physician's Choice (TPC) 4 months (95% CI 3 to 4.4) | |
| Talazoparib | Approved | Small molecule | PARP | Partial signal | NCT01945775: Progression-Free Survival (PFS): Independent Radiological Facility (IRF) Assessment (Baseline until radiologic progressive disease or death due to any cause (up to maximum duration of 36.9 months)): Talazoparib 8.6 months (95% CI 7.2 to 9.3) vs Physician's Choice Treatment 5.6 months (95% CI 4.2 to 6.7) | |
| Tamoxifen (Soltamox) | Approved | Small molecule | Estrogen receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Trastuzumab Deruxtecan | Approved | Antibody–drug conjugate | HER2 | Partial signal | NCT04494425: Progression-Free Survival (PFS) Assessed by Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Low Population (Response evaluations performed at screening, every 6 weeks (q6w) ± 1 week from randomization for 48 weeks, and then every 9 weeks (q9w) ± 1 week, starting at Week 48 until PD, up to PCD of 18 March 2024 (maximum of approximately 43.85 months)): T-DXd 13.2 months (95% CI 11.4 to 15.2) | Chemotherapy 8.1 months (95% CI 7 to 9) NCT03734029: Progression-free Survival (PFS) Based on Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer (From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years): Trastuzumab Deruxtecan (T-DXd) 10.1 months (95% CI 9.5 to 11.5) | Physician's Choice 5.4 months (95% CI 4.4 to 7.1) | |
| Vepdegestrant (Veppanu) | Approved | Small molecule | Estrogen receptor | Partial signal | NCT05654623: PFS by BICR vs fulvestrant: ESR1-mutation population median 5.0 vs 2.1 months, hazard ratio 0.58 (95% CI 0.43 to 0.78), P<0.001; all randomized patients 3.8 vs 3.6 months, hazard ratio 0.83 (95% CI 0.69 to 1.01), P=0.07 (NEJM 2025). NCT04072952: Clinical benefit rate 38% (total n=71), the trial's primary endpoint (VERITAC expansion); CBR 51.2% in ESR1-mutant patients (n=41) | |
| Afuresertib | Phase 3 | Small molecule | AKT (inhibitor) | Partial signal | NCT04851613: Primary endpoint, progression-free survival: median 7.6 months with afuresertib plus fulvestrant vs 2.0 months with placebo plus fulvestrant (sponsor topline, 2026-04-15). | |
| Anbenitamab Repodatecan | Phase 3 | Antibody–drug conjugate | HER2 (biparatopic — extracellular domains II and IV) | not yet graded | No reviewed efficacy summary in this indication | |
| Atirmociclib | Phase 3 | Small molecule | CDK4 | Partial signal | NCT06465368: Percentage of Participants With Complete Cell Cycle Arrest (CCCA) at Day 14 (Day 14): PF-07220060 + Letrozole 88.2% (95% CI 76.6-94.5) vs Letrozole Alone 17.9% (95% CI 10.0-29.8) | |
| BEBT-209 | Phase 3 | Small molecule | CDK4 (selective) | not yet graded | No reviewed efficacy summary in this indication | |
| Beruzatatug Pelitecan | Phase 3 | Antibody–drug conjugate | HER3 | not yet graded | No reviewed efficacy summary in this indication | |
| BGB-43395 | Phase 3 | Small molecule | CDK4 | not yet graded | No reviewed efficacy summary in this indication | |
| Bireociclib | Phase 3 | Small molecule | CDK2/4/6 | Reliable signal | NCT05077449: BRIGHT-2 (NCT05077449), primary endpoint median PFS: bireociclib (XZP-3287) + fulvestrant 14.7 months vs placebo + fulvestrant 7.3 months; HR 0.54 (95% CI 0.40-0.74); p<0.001 | |
| Chidamide | Phase 3 | Small molecule | HDAC | Reliable signal | NCT02482753: Investigator-assessed median PFS: 7.4 months (95% CI 5.5-9.2) chidamide+exemestane vs 3.8 months (95% CI 3.7-5.5) placebo+exemestane; hazard ratio 0.755, p=0.0336 | |
| Culmerciclib | Phase 3 | Small molecule | CDK2/CDK4/CDK6, CDK2/4/6/CDK4 | Partial signal | NCT05375461: Median investigator-assessed PFS: 16.6 months (culmerciclib + fulvestrant) vs 7.5 months (placebo + fulvestrant); HR 0.36 (95% CI 0.26-0.51), P<0.001, meeting the primary endpoint. | |
| Dalpiciclib | Phase 3 | Small molecule | CDK4 and CDK6 | not yet graded | No reviewed efficacy summary in this indication | |
| Denosumab (Xgeva) | Phase 3 | Monoclonal antibody | RANKL | not yet graded | No reviewed efficacy summary in this indication | |
| Disitamab Vedotin | Phase 3 | Antibody–drug conjugate | HER2 | Partial signal | NCT03052634: Confirmed ORR at 2.0 mg/kg Q2W: 42.9% (9/21) in HER2-overexpression and 33.3% (22/66) in HER2-low advanced breast cancer; median PFS 5.7 and 5.1 months | |
| Giredestrant | Phase 3 | Small molecule | Estrogen receptor | Partial signal | NCT04546009: persevERA (NCT04546009), primary endpoint investigator-assessed PFS: giredestrant plus palbociclib median PFS 33.1 months vs letrozole plus palbociclib 28.2 months; HR 0.89 (95% CI 0.76-1.05); p=.1553. missed | |
| HRS-6209 | Phase 3 | Small molecule | CDK4 | not yet graded | No reviewed efficacy summary in this indication | |
| HRS-8080 | Phase 3 | Small molecule | Estrogen receptor (degrader) | not yet graded | No reviewed efficacy summary in this indication | |
| Izalontamab Brengitecan | Phase 3 | Antibody–drug conjugate | EGFR + HER3 | not yet graded | No reviewed efficacy summary in this indication | |
| JS105 | Phase 3 | Small molecule | PI3K-alpha (mutant-selective) | not yet graded | No reviewed efficacy summary in this indication | |
| NTQ1062 | Phase 3 | Small molecule | AKT (inhibitor) | not yet graded | No reviewed efficacy summary in this indication | |
| Palazestrant | Phase 3 | Small molecule | Estrogen receptor | Weak signal | No reviewed efficacy summary in this indication | |
| Patritumab Deruxtecan | Phase 3 | Antibody–drug conjugate | HER3 | Weak signal | No reviewed efficacy summary in this indication | |
| Pembrolizumab | Phase 3 | Monoclonal antibody | PD-1 | Partial signal | No reviewed efficacy summary in this indication | |
| Prifetrastat | Phase 3 | Small molecule | KAT6A / KAT6B | not yet graded | No reviewed efficacy summary in this indication | |
| Sacituzumab Tirumotecan | Phase 3 | Antibody–drug conjugate | TROP2 | not yet graded | No reviewed efficacy summary in this indication | |
| Saruparib | Phase 3 | Small molecule | PARP1 inhibitor (next-gen) | not yet graded | No reviewed efficacy summary in this indication | |
| SHR-6209 | Phase 3 | Small molecule | CDK4 | not yet graded | No reviewed efficacy summary in this indication | |
| Sirolimus For Injection (Albumin-Bound) | Phase 3 | Small molecule | mTOR (mechanistic target of rapamycin complex 1), via FKBP-12 | not yet graded | No reviewed efficacy summary in this indication | |
| Taragarestrant | Phase 3 | Small molecule | Estrogen receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Tersolisib | Phase 3 | Small molecule | PI3K-alpha (mutant-selective, allosteric) | not yet graded | No reviewed efficacy summary in this indication | |
| Tibremciclib (Kangmeina) | Phase 3 | Small molecule | CDK4 and CDK6 | Partial signal | NCT05433480: Investigator-assessed PFS: tibremciclib plus fulvestrant median 16.5 months (95% CI 12.8 to 16.6) vs placebo plus fulvestrant 5.6 months (95% CI 4.5 to 9.2); HR 0.37 (95% CI 0.27 to 0.52), P<.001 | |
| Trastuzumab Pamirtecan | Phase 3 | Antibody–drug conjugate | HER2 | not yet graded | No reviewed efficacy summary in this indication | |
| Trastuzumab Rezetecan | Phase 3 | Antibody–drug conjugate | HER2 | not yet graded | No reviewed efficacy summary in this indication | |
| Utidelone | Phase 3 | Small molecule | Tubulin / microtubules | not yet graded | No reviewed efficacy summary in this indication | |
| Zoledronic Acid | Phase 3 | Small molecule | Farnesyl pyrophosphate synthase (FPPS) | not yet graded | No reviewed efficacy summary in this indication | |
| Zovegalisib | Phase 3 | Small molecule | PI3K-alpha (mutant-selective) | not yet graded | No reviewed efficacy summary in this indication | |
| SPH4336 | Phase 2/3 | Small molecule | CDK4 and CDK6 | not yet graded | No reviewed efficacy summary in this indication | |
| (Z)-Endoxifen | Phase 2 | Small molecule | Estrogen receptor (antagonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Evexomostat | Phase 2 | Small molecule | Methionine aminopeptidase 2 (MetAP2, inhibitor) | not yet graded | No reviewed efficacy summary in this indication | |
| HLX43 | Phase 2 | Antibody–drug conjugate | PD-L1 | not yet graded | No reviewed efficacy summary in this indication | |
| Notiretatug Rezetecan | Phase 2 | Antibody–drug conjugate | Nectin-4 | not yet graded | No reviewed efficacy summary in this indication | |
| Samuraciclib | Phase 2 | Small molecule | CDK7 | Partial signal | No reviewed efficacy summary in this indication | |
| ECI830 | Phase 1/2 | Small molecule | CDK2 | not yet graded | No reviewed efficacy summary in this indication | |
| GVV858 | Phase 1/2 | — | CDK2 | not yet graded | No reviewed efficacy summary in this indication | |
| IEV407 | Phase 1 | — | — | not yet graded | No reviewed efficacy summary in this indication |
Large race: only the 71 furthest-along competitors are listed; 34 more exist in this indication but aren't shown. Use the search box to compare against any of them.
Compare side by side
2 further pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(9 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Etcamah (Camizestrant) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (4)
April 2027 (1)
What to watch
May 2027 (1)
What to watch
June 2027 (1)
What to watch
December 2027 (1)
What to watch
2028 (2)
2029 (2)
2030 (1)
March 2030 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent